Search
Viking Therapeutics Inc
VKTXAdd to Watchlist
27.280USD
+0.420+1.56%
Close 10-30 16:00（ET）
3.47BMarket Cap
LossP/E TTM
After-hours 17:40 (ET)27.070USD-0.245-0.90%
After-hours 17:40 (ET)Today
+1.56%
5 Days
+11.80%
1 Month
-16.32%
6 Months
-12.51%
Year to Date
-22.46%
1 Year
-28.36%
Key Figures
26.770Open
27.833High
441.24KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.35%Turnover Ratio
26.860Prev. Close
26.310Low
11.95MTurnover
LossP/E Static
5.90P/B
0.00%Div Yield TTM
-64.04%ROA
43.15052wk High
0.10Volume Ratio
-109.96MNet Profit
127.17MShares
-4.1549EPS TTM
0.68Beta
-70.04%ROE
23.82052wk Low
12.86%Amplitude
--Gross Margin
3.47BMarket Cap
-2.48Reward/Risk
4.33%Risk Rate
Recent
Earnings
Transcripts
Viking Therapeutics Inc's Score
-0.01vs previous score
Forecast8.50
Financial Health3.80
Technical4.52
Valuation Dimensions7.70
Institutional Confidence7.00
Risk Assessment--
Media Coverage
Coverage Level
Very Low
Very High
Negative
Analyst Rating
Viking Therapeutics Inc Technical Analysis
Technical Indicators
Buy
Summary
Neutral
Moving Average
Neutral
Viking Therapeutics Inc Latest Earnings Call Transcripts
Viking Therapeutics Q3 2026 Earnings Call: VK2735 Advances, Cash Hits $960M
Viking Therapeutics Q3 2026 earnings call: VK2735 Phase III trials advanced, maintenance data remained positive, and cash reached $960 million.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-1.55/-1.07
Revenue / Forecast
0.00/0.00
Viking Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolVKTX
Number of employees36
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Fidelity Management & Research Company LLC | 4.79% |
| Vanguard Capital Management, LLC | 4.32% |
| Two Sigma Investments, LP | 3.94% |
| BlackRock Institutional Trust Company, N.A. | 3.86% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 32.52% |
| Investment Advisor/Hedge Fund | 14.02% |
| Hedge Fund | 11.27% |
| Research Firm | 5.27% |
Related Instruments
+3.19%
-0.73%
+1.41%
+2.18%
-0.19%
+7.02%
+1.15%
+3.06%
+2.20%
+1.90%
+3.50%
+1.78%
+1.40%
+2.81%
+1.71%
+13.33%
-0.47%
+4.50%
-0.24%
-0.55%Popular Instruments
51788.900
-548.500 (-1.05%)
28406.600
-658.400 (-2.27%)
7583.100
-92.600 (-1.21%)
12785.000
-56.000 (-0.44%)
62328.000
-1656.000 (-2.59%)
6120.900
-77.700 (-1.25%)
102.428
+0.026 (+0.03%)
344.630
-4.280 (-1.23%)
204.640
-9.020 (-4.22%)
3874.710
-146.240 (-3.64%)
FAQs
What is the current price of Viking Therapeutics Inc (VKTX)?
The current price of Viking Therapeutics Inc (VKTX) is 27.28.
What is the symbol of Viking Therapeutics Inc?
The ticker symbol of Viking Therapeutics Inc is VKTX.
What is the 52-week high of Viking Therapeutics Inc?
The 52-week high of Viking Therapeutics Inc is 43.15.
What is the 52-week low of Viking Therapeutics Inc?
The 52-week low of Viking Therapeutics Inc is 23.82.
What is the market capitalization of Viking Therapeutics Inc?
The market capitalization of Viking Therapeutics Inc is 3.47B.
Is Viking Therapeutics Inc (VKTX) currently rated as Buy, Hold, or Sell?
According to analysts, Viking Therapeutics Inc (VKTX) has an overall rating of Buy, with a price target of 96.50.
What is the Earnings Per Share (EPS TTM) of Viking Therapeutics Inc (VKTX)?
The Earnings Per Share (EPS TTM) of Viking Therapeutics Inc (VKTX) is -4.15.